Innovative immunotherapy approaches to treat breast cancer patients
Breast cancer is the most common malignancy in women and is the second leading cause of cancer deaths (after lung cancer).
There is a clear medical need for more efficient breast cancer treatments in terms of distant recurrence and safety and tolerance. Specific active immunotherapy carries these promises as it aims to induce tumour-specific effects while sparing non-cancerous tissues.
The Stemvac project aims to discover new antigens associated with breast cancer stem cells using highly innovative research techniques. The research will result in the development of new types of immunotherapy to fight cancer.
Consortium
Companies: GSK Biologicals, Targetome
Universities: UCL, ULg, UNamur
